Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Treasury Shares (2019 - 2025)

C4 Therapeutics' Treasury Shares history spans 6 years, with the latest figure at $2.9 million for Q3 2025.

  • For Q3 2025, Treasury Shares rose 43183.48% year-over-year to $2.9 million; the TTM value through Sep 2025 reached $2.9 million, up 43183.48%, while the annual FY2024 figure was $1.5 million, 100.65% up from the prior year.
  • Treasury Shares reached $2.9 million in Q3 2025 per CCCC's latest filing, down from $3.0 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $3.0 million in Q2 2025 to a low of $6634.0 in Q3 2024.
  • Average Treasury Shares over 4 years is $1.0 million, with a median of $704330.0 recorded in 2023.
  • Peak YoY movement for Treasury Shares: crashed 99.12% in 2024, then surged 43183.48% in 2025.
  • A 4-year view of Treasury Shares shows it stood at $465291.0 in 2022, then surged by 61.23% to $750210.0 in 2023, then surged by 100.65% to $1.5 million in 2024, then surged by 90.76% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Treasury Shares are $2.9 million (Q3 2025), $3.0 million (Q2 2025), and $1.5 million (Q4 2024).